Telomir Pharmaceuticals, Inc.
TELO
$1.45
-$0.05-3.33%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 471.46% | 66.44% | 201.37% | 677.72% | 15.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 243.84% | 14.18% | 169.37% | 529.45% | 3.38% |
| Operating Income | -243.84% | -14.18% | -169.37% | -529.45% | -3.38% |
| Income Before Tax | -249.89% | 65.15% | 68.93% | -250.07% | 6.54% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -249.89% | 65.15% | 68.93% | -250.07% | 6.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -249.89% | 65.15% | 68.93% | -250.07% | 6.54% |
| EBIT | -243.84% | -14.18% | -169.37% | -529.45% | -3.38% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -245.40% | 67.50% | 71.62% | -220.09% | 14.51% |
| Normalized Basic EPS | -245.10% | 67.47% | -44.10% | -220.25% | 14.53% |
| EPS Diluted | -245.40% | 67.50% | 71.62% | -220.09% | 14.51% |
| Normalized Diluted EPS | -245.10% | 67.47% | -44.10% | -220.25% | 14.53% |
| Average Basic Shares Outstanding | 1.35% | 7.18% | 9.46% | 9.27% | 9.27% |
| Average Diluted Shares Outstanding | 1.35% | 7.18% | 9.46% | 9.27% | 9.27% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |